MW 266.29 Da, Purity >99%. Potent specific platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor (IC50 values are 1.0 μM and 0.8 μM at PDGF α and β-receptors respectively). Cell-permeable.
146535-11-7
> 99%
Solid
266.29 Da
C16H14N2O2
2049
Synthetic
AI838772, AW493413, BCD541, CD 140B, CD140A, CD140a antigen, CD140b antigen, Component of gems 1, FLJ11090, Gemin-1, JAK2_HUMAN, JTK 10, Janus Activating Kinase 2, Janus kinase 2, Janus kinase 2 (a protein tyrosine kinase), MGC104252, MGC112732, OTTHUMP00000043260, OTTHUMP00000125198, OTTHUMP00000223567, OTTHUMP00000223568, OTTHUMP00000224066, OTTHUMP00000226924, PDGF Receptor alpha + beta, PDGF-R-alpha, PDGF-R-beta, PDGFR 2, PDGFRA, PDGFRB, Platelet derived growth factor receptor alpha, Platelet derived growth factor receptor beta, RP24-311F12.2, SCAN1, SMA, SMA 1, SMA 2, SMA 3, SMA 4, SMN1, SMN2, SMNT, SMN_HUMAN, Survival motor neuron protein, Survival of motor neuron 1, telomeric, T-BCD541, THCYT3, TYDP, TYDP1_HUMAN, Tyr-DNA phosphodiesterase 1, Tyrosine-protein kinase JAK2, Tyrosyl-DNA phosphodiesterase 1, kinase Jak2
MW 266.29 Da, Purity >99%. Potent specific platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor (IC50 values are 1.0 μM and 0.8 μM at PDGF α and β-receptors respectively). Cell-permeable.
146535-11-7
> 99%
Solid
266.29 Da
C16H14N2O2
2049
Synthetic
Soluble in DMSO to 100 mM. Soluble in ethanol to 10 mM.
6,7-Dimethoxy-2-phenylquinoxaline
Potent specific platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor (IC50 values are 1.0 μM and 0.8 μM at PDGF α and β-receptors respectively). Cell-permeable.
COC1=C(C=C2C(=C1)N=CC(=N2)C3=CC=CC=C3)OC
InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3
QNOXYUNHIGOWNY-UHFFFAOYSA-N
6,7-dimethoxy-2-phenylquinoxaline
Ambient - Can Ship with Ice
-20°C
-20°C
It is important to note that this product is reported to be light sensitive, Store in the dark, Store under desiccating conditions
This supplementary information is collated from multiple sources and compiled automatically.
JAK2 also known as Janus kinase 2 is a non-receptor tyrosine kinase with a mass of approximately 130 kDa. It is involved in cytokine receptor signaling and is broadly expressed in hematopoietic cells including stem cells and progenitor cells. TDP1 or tyrosyl-DNA phosphodiesterase 1 functions in DNA repair and is expressed in various tissues notably the brain and muscle. PDGFR alpha and beta are receptor tyrosine kinases involved in cellular proliferation differentiation and development. They are expressed in the mesenchymal cells and skin tissues. SMN or survival motor neuron protein interacts with Gemin proteins to form a complex. This complex is highly expressed in motor neurons and aids in the assembly of spliceosomal snRNPs.
JAK2 mediates the action of growth factors and cytokines important for cell proliferation and hematopoiesis. It commonly partners with STAT proteins to control gene expression. TDP1 fixes DNA single-strand breaks apart from functioning independently it sometimes partners with other DNA repair proteins. PDGFR alpha and beta drive pathways controlling cell growth and migration often forming dimers upon ligand binding. SMN often in association with Gemin 1 plays a critical role in RNA processing and the assembly of the spliceosome complex which is indispensable for mRNA splicing.
JAK2 occupies a central role in the JAK-STAT signaling pathway which impacts cell survival and apoptosis and interacts closely with STAT5. TDP1 is involved in the base excision repair pathway maintaining genome integrity and relating to PARP1 protein functions. PDGFR alpha and beta contribute significantly to the PI3K/AKT pathway and MAPK/ERK signaling involved in cell growth and proliferation operating in conjunction with proteins like PI3K and RAS. SMN’s involvement in the SMN-Gemin complex is critical for the biogenesis of snRNPs impacting RNA splicing pathways.
Mutations in JAK2 are frequently linked to myeloproliferative neoplasms such as polycythemia vera often seen alongside mutations in the CALR gene. TDP1 when defective plays a role in neurological disorders including spinocerebellar ataxia with axonal neuropathy sometimes in conjunction with APTX mutations. PDGFR alpha and beta aberrations relate to cancers such as glioblastoma often found with IDH1 mutations. SMN mutations lead to spinal muscular atrophy where there is interaction with proteins like ubiquitin and survival-related factors in cells.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab141170, AG 1296, protein tyrosine kinase inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com